vVARDIS Holding AG develops and commercializes a peptide-enabled technology platform called Curodont® for the treatment of early-stage cavities. The company’s flagship products, Curodont® Repair Fluoride Plus and Curodont® Repair, are designed to arrest or reverse early cavities by supporting natural enamel remineralization without drilling or injections. These products are marketed to dental professionals in the United States, Europe, and other international…
vVARDIS Holding AG develops and commercializes a peptide-enabled technology platform called Curodont® for the treatment of early-stage cavities. The company’s flagship products, Curodont® Repair Fluoride Plus and Curodont® Repair, are designed to arrest or reverse early cavities by supporting natural enamel remineralization without drilling or injections. These products are marketed to dental professionals in the United States, Europe, and other international markets.
vVARDIS Holding AG generates revenue primarily through the sale of its Curodont® products to dental practices and distributors. In the United States, Curodont® Repair Fluoride Plus is distributed exclusively through Henry Schein under a hybrid model that combines the company’s direct sales force with Henry Schein’s distribution network. The company’s net revenue was $30.2 million for the year ended December 31, 2025, and $28.6 million for the six months ended June 30, 2026, reflecting strong year-over-year growth. Gross margins reached 74.2% and 86.4% for those respective periods, driven by the asset-light nature of its business model.
The company operates through the following segments:
- Curodont® Repair Fluoride Plus: This segment sells the company’s flagship product in the United States, which contains sodium fluoride and the proprietary P11-4 peptide. It is regulated as an over-the-counter drug product by the U. S. Food and Drug Administration. This product generated the vast majority of the company’s revenues following its U. S. commercial launch in January 2024.
- Curodont® Repair: This segment markets a fluoride-free formulation of the Curodont® platform in international markets including the United Kingdom, Switzerland, Italy, Germany, Poland, and the Czech Republic. It is regulated as a medical device in these jurisdictions. The product contains the same P11-4 peptide technology but does not include sodium fluoride as an active ingredient.
vVARDIS Holding AG occupies a unique position in the dental care industry as the first mover in a new restorative category for early-stage cavities. The company believes there are currently no commercially available products that directly compete with Curodont® in providing a clinically validated, non-invasive restorative treatment for early-stage cavities. Its competitive advantages include a robust body of clinical evidence from over 250 publications, a growing intellectual property estate with 83 issued patents globally as of June 30, 2026, and an asset-light manufacturing model supported by specialized third-party partners.
vVARDIS Holding AG serves dental professionals including general dentists, dental hygienists, and dental service organizations (DSOs). As of June 30, 2026, the company had sold its flagship Curodont® products to over 20,000 of the approximately 110,000 general dental practices in the United States. The company also works with major DSOs such as Heartland, Aspen Dental, Pacific Dental Services, and Smile Brands to drive adoption across affiliated practices.